Substituted sodium 1H-pyrazol-5-olate
View Patent ↗The present application relates to sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate, to processes for its preparation, to its use for the treatment and/or prophylaxis of diseases and to its use for the preparation of medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing.
1. Sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate corresponding to the compound of the formula (II)
2. Compound of the formula (II) according to claim 1 , wherein the compound of the formula (II) is present in crystalline form.
3. Process for preparing the compound of the formula (II) according to claim 1 , comprising reacting the compound of the formula (I)
in a solvent with sodium hydroxide or aqueous sodium hydroxide solution or a sodium salt, optionally with the addition of a base.
4. Process for preparing the compound of the formula (II) according to claim 3 , comprising reacting the compound of the formula (I) in a solvent with aqueous sodium hydroxide solution, optionally with the addition of a base.
5. Process for preparing the compound of the formula (II) according to claim 3 , comprising reacting the compound of the formula (I) in a solvent with aqueous sodium hydroxide solution with the addition of triethylamine.
6. A pharmaceutical composition comprising the compound according to claim 1 in combination with an inert, non-toxic, pharmaceutically suitable auxiliary.
7. A pharmaceutical composition comprising the compound according to claim 1 in combination with a further active compound.
8. A pharmaceutical composition comprising the compound according to claim 2 in combination with an inert, non-toxic, pharmaceutically suitable auxiliary.
9. A pharmaceutical composition comprising the compound according to claim 2 in combination with a further active compound.